{"product_id":"snpx-vrio-analysis","title":"Synaptogenix, Inc. (SNPX): VRIO Analysis [Mar-2026 Updated]","description":"\u003cbr\u003e\u003cp\u003eIs Synaptogenix, Inc. (SNPX) truly positioned for long-term success? This VRIO analysis cuts straight to the core, examining the Value, Rarity, Inimitability, and Organization of its key resources to determine if a sustainable competitive advantage truly exists. Dive in below to see the definitive verdict on whether their current strengths are a fleeting edge or a lasting fortress.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e1. Bryostatin-1 Drug Candidate Platform\u003c\/strong\u003e\n\u003c\/h2\u003e\n\n\u003cp\u003eYou’re looking at Synaptogenix, Inc. (SNPX) and trying to figure out if their lead asset, Bryostatin-1, is a durable competitive weapon. Honestly, it’s a classic biotech story: massive potential upside balanced by massive execution risk. The core value proposition is clear - treating devastating neurodegenerative diseases like Alzheimer's - but the path to realizing that value is anything but certain right now.\u003c\/p\u003e\n\n\u003cp\u003eThe platform’s value is tied directly to future regulatory success, which is the biggest lever here. If they get this through the FDA for Alzheimer's or Fragile X syndrome, the margins on a novel small molecule therapy are fantastic. Still, the company is in a transitional phase as of mid-2025, navigating leadership changes and strategic repositioning, which can definitely impact clinical momentum.\u003c\/p\u003e\n\n\u003cp\u003eHere’s the quick math on current program spending: the Fragile X trial is estimated at a total of $2.0 million, of which only about $100,000 was incurred by March 31, 2025. Meanwhile, the Cleveland Clinic MS Phase 1 trial, estimated at $2.0 million total, had already burned through approximately $743,000 by that same date. What this estimate hides is the massive capital requirement for a Phase 3 trial, which is still ahead.\u003c\/p\u003e\n\n\u003cp\u003eThe rarity isn't the compound itself, which has a history in NCI cancer studies involving over 1,500 people, but rather Synaptogenix, Inc.'s specific, proprietary formulation and the clinical data package they are building for these new indications. They are actively protecting this through patent applications and, failing that, through trade secrets and proprietary methods.\u003c\/p\u003e\n\n\u003cp\u003eThe imitatibility barrier is high only in the clinical and regulatory sense. Anyone can study the underlying science of activating protein kinase C (PKC) enzymes, but replicating the specific safety and efficacy data needed for an FDA submission is incredibly difficult and time-consuming. Still, the underlying science is established, meaning a competitor with deep pockets could theoretically try to develop a similar molecule.\u003c\/p\u003e\n\n\u003cp\u003eOrganizationally, I peg them as moderate. They have secured IND authorization for the MS trial, which is a win, but the mid-2025 leadership transitions suggest internal focus might be fractured. If onboarding takes 14+ days longer than planned, clinical timelines slip, and that erodes the temporary advantage.\u003c\/p\u003e\n\n\u003cp\u003eThe competitive advantage is currently \u003cstrong\u003eTemporary\u003c\/strong\u003e. The entire upside hinges on successful clinical outcomes, which remain a long shot until Phase 2b or Phase 3 data is in hand. They have a clear runway for the near-term trials, but no sustained advantage exists without a market-approved product.\u003c\/p\u003e\n\n\u003cp\u003eHere is the VRIO breakdown:\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eVRIO Dimension\u003c\/td\u003e\n\u003ctd\u003eAssessment for Bryostatin-1 Platform\u003c\/td\u003e\n\u003ctd\u003eKey Data Point (as of 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh potential for high-margin revenue from commercialization in AD, FXS, or MS.\u003c\/td\u003e\n\u003ctd\u003eNot yet commercialized; value is purely contingent on future success.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eProprietary formulation and exclusive development rights for these indications are potentially unique.\u003c\/td\u003e\n\u003ctd\u003eUtilizes a large safety database from NCI cancer studies involving over \u003cstrong\u003e1,500\u003c\/strong\u003e subjects.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eHigh barrier to copy the specific clinical trial data and navigate the regulatory pathway.\u003c\/td\u003e\n\u003ctd\u003eMS trial estimated cost: \u003cstrong\u003e$2.0 million\u003c\/strong\u003e; FXS trial estimated cost: \u003cstrong\u003e$2.0 million\u003c\/strong\u003e.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eModerate; strategic repositioning and leadership changes introduce execution risk.\u003c\/td\u003e\n\u003ctd\u003eIncurred expenses for FXS trial: approx. \u003cstrong\u003e$100,000\u003c\/strong\u003e as of March 31, 2025.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eYou need to see a clear path through the MS Phase 1 trial, which is fully funded, to convert this temporary advantage into something more tangible. The next critical milestone is seeing patient data from the Cleveland Clinic study, which is using 7-tesla MRI to look for biomarkers.\u003c\/p\u003e\n\n\u003cp\u003eStrategy: Finance to finalize the 13-week cash flow projection, incorporating the MS trial burn rate, by Friday.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e2. Key Academic Licensing Agreements\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e The agreements provide the legal foundation for developing the Bryostatin-1 platform, covering both Bryostatin-1 and bryologs for various neurological and CNS indications.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e While early-stage biotech licensing is common, the specific terms with Stanford University and Mount Sinai are unique, detailing royalty structures such as 2.0% to 3.0% on net sales over $250 million with Mount Sinai, and 1.5% to 4.5% royalty potential with Stanford.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low, as the specific contractual terms are not replicable. Potential milestone payments to Stanford are structured up to $3.7 million.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e Moderate. The agreements are established, but the financial commitment to date is relatively low compared to potential upside. Cumulative payments to Mt. Sinai were approximately $190,000 (licensing fees of $115,000 plus development\/patent fees of approximately $75,000) as of March 31, 2023. The annual license maintenance fee to Stanford is $10,000.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary. As of March 31, 2023, no royalties nor milestone payments had been required by Stanford under the revised agreement.\u003c\/p\u003e\n\u003cp\u003eThe key financial obligations and terms associated with the foundational academic licenses are summarized below:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eAgreement Party\u003c\/th\u003e\n\u003cth\u003eInitial\/Upfront Payment\u003c\/th\u003e\n\u003cth\u003eAnnual Fee\u003c\/th\u003e\n\u003cth\u003ePotential Milestones\u003c\/th\u003e\n\u003cth\u003eRoyalty Rate (Net Sales)\u003c\/th\u003e\n\u003cth\u003eData Cutoff\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eStanford (Bryologs)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$70,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eUp to \u003cstrong\u003e$3.7 million\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.5%\u003c\/strong\u003e to \u003cstrong\u003e4.5%\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e03\/31\/2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMount Sinai\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$115,000\u003c\/strong\u003e (Licensing Fee Portion)\u003c\/td\u003e\n\u003ctd\u003eNone Stated\u003c\/td\u003e\n\u003ctd\u003eNot Specified\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.0%\u003c\/strong\u003e (up to $250M), \u003cstrong\u003e3.0%\u003c\/strong\u003e (over $250M)\u003c\/td\u003e\n\u003ctd\u003e03\/31\/2023\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eAdditional related financial data includes:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eEstimated cost to initiate and produce sufficient quantities of synthetic bryostatin drug product is approximately \u003cstrong\u003e$1.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe Company incurred approximately \u003cstrong\u003e$9,878\u003c\/strong\u003e for development with Stanford University as of March 31, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e3. Rebranded Corporate Identity (TAO Synergies\/TAOX)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe rebranding of Synaptogenix, Inc. to TAO Synergies Inc. and the subsequent ticker change to TAOX on the Nasdaq Capital Market represents a definitive strategic pivot.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eValue:\u003c\/strong\u003e Signals a clear, albeit risky, strategic pivot to the market, potentially attracting new capital by aligning with the high-growth AI token sector.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity:\u003c\/strong\u003e The specific rebranding from a biotechnology firm to a pure-play AI token treasury focused on TAO is quite rare in the public equity market.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability:\u003c\/strong\u003e Low; the name and ticker change itself is a one-time event, but the underlying strategy of focusing on TAO staking is imitable by other entities.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization:\u003c\/strong\u003e High; the management executed the rebrand and ticker change (SNPX to TAOX) effectively by \u003cstrong\u003eJuly 1, 2025\u003c\/strong\u003e, with the name change effective on \u003cstrong\u003eJune 26, 2025\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage:\u003c\/strong\u003e Temporary; the advantage is the initial market surprise and clarity of direction provided by the strategic shift.\u003c\/p\u003e\n\u003cp\u003eThe transition is underpinned by specific corporate and market actions:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe new ticker symbol \u003cstrong\u003eTAOX\u003c\/strong\u003e commenced trading on Nasdaq on \u003cstrong\u003eJuly 1, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe company's previous ticker was \u003cstrong\u003eSNPX\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eThe strategy centers on the acquisition and staking of the TAO token, described as the leading AI token by market capitalization and adoption.\u003c\/li\u003e\n\u003cli\u003eRevenue generation is planned through both staking yield and potential token appreciation from the TAO holdings.\u003c\/li\u003e\n\u003cli\u003eExecutive Chairman Joshua Silverman emphasized this transition as a strategic move to create long-term shareholder value.\u003c\/li\u003e\n\u003cli\u003eA new corporate website detailing the TAO integration was scheduled to launch in the summer of \u003cstrong\u003e2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial and stock data points associated with the transition and the new entity include:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue (SNPX Pre-Rebrand Context)\u003c\/td\u003e\n\u003ctd\u003eValue (TAOX Post-Rebrand Context - Dec 7, 2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.24M\u003c\/strong\u003e (SNPX context)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$44.98M\u003c\/strong\u003e or \u003cstrong\u003e$42.84M\u003c\/strong\u003e or \u003cstrong\u003e$42,702,183\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week High\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$11.98\u003c\/strong\u003e or \u003cstrong\u003e$11.9799\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Low\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.84\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrevious Closing Price (Prior to Dec 7, 2025)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$5.990\u003c\/strong\u003e or \u003cstrong\u003e$5.99\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAverage Trading Volume\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e20.00k\u003c\/strong\u003e (Float context)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e211.63K\u003c\/strong\u003e or \u003cstrong\u003e391,952\u003c\/strong\u003e (Average Volume)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Consensus Rating (SNPX)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2.0\u003c\/strong\u003e ('Outperform') based on 1 firm\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAnalyst Price Target (SNPX)\u003c\/td\u003e\n\u003ctd\u003eAverage: \u003cstrong\u003e$14.00\u003c\/strong\u003e (Implied \u003cstrong\u003e271.35%\u003c\/strong\u003e upside from $3.77)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eSpecific operational data related to the new strategy:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe company announced an initial TAO acquisition and appointed BitGo as custodian on \u003cstrong\u003eJune 24, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTAOX traded at a price of \u003cstrong\u003e$6.31\u003c\/strong\u003e on December 7, 2025, reflecting a \u003cstrong\u003e+5.34%\u003c\/strong\u003e move since market open that day.\u003c\/li\u003e\n\u003cli\u003eThe daily trading volume on that date was reported as \u003cstrong\u003e$62.00\u003c\/strong\u003e shares or \u003cstrong\u003e133.66K\u003c\/strong\u003e shares.\u003c\/li\u003e\n\u003cli\u003eReported TAO token holdings reached \u003cstrong\u003e54,058\u003c\/strong\u003e through acquisition and staking as of October 20, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e4. AI Token (TAO) Treasury Strategy\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAims to generate capital appreciation and yield from a high-growth, albeit volatile, digital asset class.\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eAmount\/Value\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial TAO Acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal Target TAO Holdings\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTAO Fixed Supply\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e21 million\u003c\/strong\u003e tokens\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eReported Stock Jump Post-Announcement\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e44 per cent\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eVery rare for a former biotech; this is an aggressive treasury management approach.\u003c\/p\u003e\n\u003cp\u003eThe focus is exclusively on TAO, the native cryptocurrency of Bittensor, a decentralized blockchain network for machine learning and AI. The strategy leverages the token's scarcity against surging global demand for AI development.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; other small-cap firms could adopt a similar strategy, but execution speed matters.\u003c\/p\u003e\n\u003cp\u003eThe initial deployment of $10 million and securing $5.5 million in financing at a $3.00 per share conversion price for Series D preferred stock demonstrates execution speed.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eHigh; the commitment, including appointing a custodian like BitGo, shows organizational alignment.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAppointed BitGo to provide qualified custody, staking, and trading services in regulated, insured cold storage.\u003c\/li\u003e\n\u003cli\u003eEngaged James Altucher as the Crypto TAO strategy leader.\u003c\/li\u003e\n\u003cli\u003eCommenced revenue generation through TAO staking immediately following the initial purchase.\u003c\/li\u003e\n\u003cli\u003eCompany is rebranding from Synaptogenix, Inc. (SNPX) to TAO Synergies Inc. with ticker TAOX effective July 1, 2025.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eTemporary; sustained advantage depends on market timing and superior TAO performance versus peers.\u003c\/p\u003e\n\u003cp\u003eThe company reported a 18% return over the past six months (as of June 24, 2025) prior to the full impact of the strategy announcement.\u003c\/p\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e5. TAO Staking Operations for Yield Generation\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe TAO staking operation represents a strategic pivot to generate non-traditional revenue streams for Synaptogenix, Inc.\u003c\/p\u003e\n\u003cp\u003e\n    \u003c\/p\u003e\u003ctable\u003e\n        \u003cthead\u003e\n            \u003ctr\u003e\n                \u003ctd\u003eVRIO Attribute\u003c\/td\u003e\n                \u003ctd\u003eAssessment\u003c\/td\u003e\n                \u003ctd\u003eSupporting Financial\/Statistical Data\u003c\/td\u003e\n            \u003c\/tr\u003e\n        \u003c\/thead\u003e\n        \u003ctbody\u003e\n            \u003ctr\u003e\n                \u003ctd\u003eValue\u003c\/td\u003e\n                \u003ctd\u003eCreates a direct, recurring revenue stream from the treasury asset.\u003c\/td\u003e\n                \u003ctd\u003eTrailing EPS of \u003cstrong\u003e-$10.08\u003c\/strong\u003e in 2025; Staking yield target of \u003cstrong\u003e8-12%\u003c\/strong\u003e annually.\u003c\/td\u003e\n            \u003c\/tr\u003e\n            \u003ctr\u003e\n                \u003ctd\u003eRarity\u003c\/td\u003e\n                \u003ctd\u003eFor a Nasdaq-listed entity to make staking a core revenue pillar is unusual.\u003c\/td\u003e\n                \u003ctd\u003eInitial \u003cstrong\u003e$10 million\u003c\/strong\u003e TAO token acquisition announced.\u003c\/td\u003e\n            \u003c\/tr\u003e\n            \u003ctr\u003e\n                \u003ctd\u003eImitability\u003c\/td\u003e\n                \u003ctd\u003eLow, as the specific staking parameters and yield targets are proprietary to their operations.\u003c\/td\u003e\n                \u003ctd\u003eTargeted yield range of \u003cstrong\u003e8%\u003c\/strong\u003e to \u003cstrong\u003e12%\u003c\/strong\u003e per annum.\u003c\/td\u003e\n            \u003c\/tr\u003e\n            \u003ctr\u003e\n                \u003ctd\u003eOrganization\u003c\/td\u003e\n                \u003ctd\u003eHigh; they have operationalized the staking process with institutional support.\u003c\/td\u003e\n                \u003ctd\u003eInitial acquisition funded by cash reserves of \u003cstrong\u003e$19.6 million\u003c\/strong\u003e (as of 9\/30\/2024); Custody via BitGo Trust.\u003c\/td\u003e\n            \u003c\/tr\u003e\n            \u003ctr\u003e\n                \u003ctd\u003eCompetitive Advantage\u003c\/td\u003e\n                \u003ctd\u003eTemporary; staking yields are public knowledge and subject to network changes.\u003c\/td\u003e\n                \u003ctd\u003eLong-term holding goal of \u003cstrong\u003e$100 million\u003c\/strong\u003e in TAO holdings.\u003c\/td\u003e\n            \u003c\/tr\u003e\n        \u003c\/tbody\u003e\n    \u003c\/table\u003e\n\n\u003cp\u003eThe operational framework includes:\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eInitial TAO acquisition amount: \u003cstrong\u003e$10 million\u003c\/strong\u003e.\u003c\/li\u003e\n    \u003cli\u003eTotal target holding value: \u003cstrong\u003e$100 million\u003c\/strong\u003e.\u003c\/li\u003e\n    \u003cli\u003eRecent financing secured to support strategy: \u003cstrong\u003e$5.5 million\u003c\/strong\u003e.\u003c\/li\u003e\n    \u003cli\u003eTAO token supply scarcity: Total supply of \u003cstrong\u003e21 million\u003c\/strong\u003e tokens.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eThe direct revenue generation mechanism is quantified by the expected yield:\u003c\/p\u003e\n\u003cul\u003e\n    \u003cli\u003eExpected Annual Yield Range: \u003cstrong\u003e8%\u003c\/strong\u003e to \u003cstrong\u003e12%\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e6. Expert Consulting Agreement (James Altucher)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial TAO token acquisition planned at \u003cstrong\u003e$10,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTotal TAO token acquisition target set at \u003cstrong\u003e$100,000,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eTargeted revenue generation through TAO staking yield estimated at \u003cstrong\u003e8-12%\u003c\/strong\u003e annually.\u003c\/li\u003e\n\u003cli\u003eThe strategy aims for capital appreciation on the TAO token investment.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eInitial TAO acquisition of \u003cstrong\u003e$10,000,000\u003c\/strong\u003e was stated to be over two times the Company's market capitalization of approximately \u003cstrong\u003e$5,000,000\u003c\/strong\u003e (as of June 24, 2025).\u003c\/li\u003e\n\u003cli\u003eAccess to a well-known crypto\/AI expert leading a corporate treasury strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eAmount\/Figure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial TAO Investment Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal TAO Investment Target\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eApproximate SNPX Market Cap (June 2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFinancing Secured (Series D Preferred Stock)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe specific contract terms are unique to the firm.\u003c\/li\u003e\n\u003cli\u003eThe agreement has a term of one-year.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eConsulting Compensation Component\u003c\/td\u003e\n\u003ctd\u003eDetail\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrants Granted\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1,200,000\u003c\/strong\u003e common shares\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWarrant Exercise Price Range\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$4.00\u003c\/strong\u003e to \u003cstrong\u003e$12.00\u003c\/strong\u003e per share\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAgreement Term\u003c\/td\u003e\n\u003ctd\u003eOne-year\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe organization secured 5,500 shares of Series D convertible preferred stock at a stated value of $1,000 per share as part of related financing agreements.\u003c\/li\u003e\n\u003cli\u003eThe Company has commenced generating revenue through TAO staking.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cul\u003e\n\u003cli\u003eKey Organizational Actions Related to Strategy:\n\u003c\/li\u003e\n\u003cli\u003eAppointed BitGo for qualified custody, staking, and trading services.\u003c\/li\u003e\n\u003cli\u003eSecured $5.5 million in financing with a conversion price of $3.00 per share.\u003c\/li\u003e\n\u003cli\u003eBegan staking TAO tokens directly from qualified custody.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003ePotential for yield generation from TAO staking, targeted at 8-12% annually.\u003c\/li\u003e\n\u003cli\u003eThe initial $10,000,000 TAO acquisition represents a significant allocation of capital relative to the $5,000,000 market capitalization.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e7. Nasdaq Public Listing (Ticker: TAOX)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003eThe public listing status on the Nasdaq Capital Market is a critical component of the firm's structure, transitioning from SNPX to TAOX effective July 1, 2025.\u003c\/p\u003e\n\n\u003ch3\u003eValue\u003c\/h3\u003e\n\u003cp\u003eAccess to public equity markets for capital raises is provided via the Nasdaq listing. Specific capital events include:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSecured financing of \u003cstrong\u003e$5.0 million\u003c\/strong\u003e via Series C convertible preferred stock.\u003c\/li\u003e\n\u003cli\u003eSecured financing of \u003cstrong\u003e$5.5 million\u003c\/strong\u003e via Series D convertible preferred stock.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eFinancial position data around the transition period:\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003eSNPX (Pre-Pivot Data Point)\u003c\/th\u003e\n\u003cth\u003eTAOX (Post-Pivot Data Point as of 11\/28\/2025)\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1.389,815\u003c\/strong\u003e \/ \u003cstrong\u003eapproximately 1.3 million\u003c\/strong\u003e (as of 9\/30\/2024)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e7.13 M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMarket Capitalization\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10.91 million\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$43.41 M\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCash on Hand\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$19.6 million\u003c\/strong\u003e (as of September 30, 2024)\u003c\/td\u003e\n\u003ctd\u003eN\/A\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eRarity\u003c\/h3\u003e\n\u003cp\u003eThe rarity is associated with the successful maintenance of the listing status through a drastic strategic pivot.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eTicker change from SNPX to TAOX effective July 1, 2025.\u003c\/li\u003e\n\u003cli\u003eThe company is positioned as the first pure-play public company focused on the convergence between cryptocurrency and artificial intelligence (AI) via its TAO treasury strategy.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eImitability\u003c\/h3\u003e\n\u003cp\u003eThe existing listing status on the Nasdaq Capital Market cannot be easily replicated by competitors without undergoing the full IPO or direct listing process.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eHistorical Stock Price Range (SNPX)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$0.00\u003c\/strong\u003e to \u003cstrong\u003e$47.00\u003c\/strong\u003e (All-time high on July 13, 2023)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week High (SNPX as of 12\/03\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.94\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003e52-Week Low (SNPX as of 04\/07\/2025)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$1.84\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003ch3\u003eOrganization\u003c\/h3\u003e\n\u003cp\u003eThe organization successfully navigated the requirements for the listing transition.\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eThe CUSIP for the common stock remained \u003cstrong\u003eunchanged\u003c\/strong\u003e during the ticker symbol transition.\u003c\/li\u003e\n\u003cli\u003eThe company reported total TAO tokens increased to \u003cstrong\u003e54,058 tokens\u003c\/strong\u003e (42 days prior to 11\/28\/2025).\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ch3\u003eCompetitive Advantage\u003c\/h3\u003e\n\u003cp\u003eBeing publicly traded provides a structural advantage over private peers in accessing capital and visibility.\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eLast Closing Price (SNPX)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e$7.85\u003c\/strong\u003e \/ \u003cstrong\u003e$33.77\u003c\/strong\u003e (as of 12\/03\/2025)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice to Earnings Ratio (SNPX)\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e-0.30\u003c\/strong\u003e (Negative Earnings) \/ \u003cstrong\u003e-0.74\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePrice to Book Value per Share Ratio (TAOX)\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1.38\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e8. Remaining Pre-clinical\/Clinical Pipeline Assets\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\n\u003ch\u003eValue\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003ePotential for future value creation if any non-Bryostatin-1 assets gain traction or are licensed out. The Company held \u003cstrong\u003e$19.6 million\u003c\/strong\u003e in cash and cash equivalents as of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e, which provides a financial buffer to potentially pursue or out-license these secondary assets.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eRarity\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eStandard for a biotech, but the depth of the remaining pipeline is likely shallow post-pivot. Specific assets include proprietary analogs currently under evaluation for Spinal Cord Injury via a collaboration announced in \u003cstrong\u003eJuly 2024\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eImitability\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eModerate; the underlying science is known, but the specific data packages are unique. The data packages relate to Bryostatin-1's regenerative mechanisms for indications beyond Alzheimer's, such as Fragile X syndrome (which received Orphan Drug Designation) and MS, stroke, and TBI.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eOrganization\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eLow; the focus shift suggests these assets are not being actively developed or funded internally, despite the cash position. The Company announced a Special Committee in \u003cstrong\u003eDecember 2024\u003c\/strong\u003e to explore strategic opportunities utilizing balance sheet strength. As of \u003cstrong\u003eMay 14, 2025\u003c\/strong\u003e, there were \u003cstrong\u003e1,389,815\u003c\/strong\u003e shares of common stock issued and outstanding.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003ch\u003eCompetitive Advantage\u003c\/h\u003e\n\u003c\/p\u003e\u003cp\u003eNone; these are likely stranded assets with diminishing value unless actively pursued. The company's CEO indicated an exploration of alternatives to previous research and development programs.\u003c\/p\u003e\n\n\u003cp\u003e\n\u003cstrong\u003eKnown Pipeline Activities\/Indications Beyond Primary Focus:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eAsset\/Indication Area\u003c\/td\u003e\n\u003ctd\u003eStatus\/Context\u003c\/td\u003e\n\u003ctd\u003eDate\/Financial Context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eProprietary Analogs\u003c\/td\u003e\n\u003ctd\u003eCollaboration for Spinal Cord Injury study\u003c\/td\u003e\n\u003ctd\u003eAnnounced \u003cstrong\u003eJuly 2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFragile X Syndrome\u003c\/td\u003e\n\u003ctd\u003eOrphan Drug Designation for Bryostatin-1\u003c\/td\u003e\n\u003ctd\u003eHistorical context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMultiple Sclerosis (MS)\u003c\/td\u003e\n\u003ctd\u003ePreclinical studies noted\u003c\/td\u003e\n\u003ctd\u003eHistorical context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eStroke\/Traumatic Brain Injury (TBI)\u003c\/td\u003e\n\u003ctd\u003ePreclinical studies noted\u003c\/td\u003e\n\u003ctd\u003eHistorical context\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003e\n\u003cstrong\u003eFinancial Context Supporting Organizational Capacity:\u003c\/strong\u003e\n\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCash and cash equivalents: \u003cstrong\u003e$19.6 million\u003c\/strong\u003e as of \u003cstrong\u003eSeptember 30, 2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eCommon shares outstanding: \u003cstrong\u003e1,389,815\u003c\/strong\u003e as of \u003cstrong\u003eMay 14, 2025\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eExpected cash burn rate: Dramatically reduced.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cbr\u003e\u003ch2\u003eSynaptogenix, Inc. (SNPX) - VRIO Analysis: \u003cstrong\u003e9. Capital Structure Context (Mid-2025 Data)\u003c\/strong\u003e\n\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eValue\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eShares outstanding as of May 14, 2025: \u003cstrong\u003e1,389,815\u003c\/strong\u003e. Q1 2025 EPS: \u003cstrong\u003e$0.04\u003c\/strong\u003e. Q1 2025 Net Income: \u003cstrong\u003e$385,169\u003c\/strong\u003e. Market Capitalization: \u003cstrong\u003e$11,000,000\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eRarity\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eSpecific share count of \u003cstrong\u003e1,389,815\u003c\/strong\u003e and Q1 2025 EPS of \u003cstrong\u003e$0.04\u003c\/strong\u003e are factual data points defining the current structure.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eImitability\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNot applicable; this is a historical fact, not a resource.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eOrganization\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eModerate; management must navigate existing preferred stock, warrant structures, and the new TAO treasury allocation.\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003eCompetitive Advantage\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eNone; this is the starting line, not a competitive edge.\u003c\/p\u003e\n\u003cp\u003eFinance: Sensitivity Analysis Context (TAO Treasury Value vs. Q1 2025 EPS Base)\u003c\/p\u003e\n\u003ctable\u003e\n\u003cthead\u003e\n\u003ctr\u003e\n\u003ctd\u003eMetric\u003c\/td\u003e\n\u003ctd\u003eValue\u003c\/td\u003e\n\u003ctd\u003eContext\/Date\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eShares Outstanding\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e1,389,815\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eMay 14, 2025 (Mandated)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eQ1 2025 EPS\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$0.04\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eQ1 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTarget TAO Treasury Size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$100,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eAnnounced Strategy\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInitial TAO Purchase\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$10,000,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eInitial Acquisition\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSeries D Financing\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$5,500,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eJune 2025\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cp\u003eFactors influencing capital structure and potential dilution:\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eSeries D Preferred Stock Conversion Price: \u003cstrong\u003e$3.00\u003c\/strong\u003e per share.\u003c\/li\u003e\n\u003cli\u003eSeries D Stated Value per Share: \u003cstrong\u003e$1,000\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSeries D Warrants Exercise Price: \u003cstrong\u003e$3.00\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eSeries C Preferred Stock Quarterly Dividend: \u003cstrong\u003e5.0%\u003c\/strong\u003e cash accrual.\u003c\/li\u003e\n\u003cli\u003eSeries C Conversion Price: \u003cstrong\u003e$4.00\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003eFull-Time Employees: \u003cstrong\u003e4\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":45516254249109,"sku":"snpx-vrio-analysis","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/snpx-vrio-analysis.png?v=1740219575","url":"https:\/\/dcf-model.com\/es\/products\/snpx-vrio-analysis","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}